Venlo the Netherlands (ots) – Qiagen N.V. (Nasdaq: QGEN) (Frankfurt:
QIA) has posted its 2016 Annual Report on its website at http://ots.de/YwER5. QIAGEN’s Annual Report on Form 20-F for the year ended December 31, 2016 has been filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2017, a copy of which can be found on the website of the SEC at www.sec.gov or in the ‚Financial Information‘ section of the ‚Investors‘ section of our website at
http://www.qiagen.com/About-Us/Investors/. QIAGEN will provide
printed copies of the 2016 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2016 Annual Report please contact: [email protected].

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2016, QIAGEN employed approximately 4,700 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.

Digital press kit: http://www.ots.at/pressemappe/DE76066/aom

Rückfragen & Kontakt:

Investor Relations
[email protected]

John Gilardi
Vice President, Head of Corporate Communications and Investor
Relations
19300 Germantown Road | Germantown MD 20874 USA
Phone +1-240-686-2222 | Fax +1-240-686-22238
QIAGEN-Str. 1 | 40724 Hilden Germany
Phone +49-2103-29-11711 | Fax +49-2103-29-21711

Dr. Sarah Fakih
Associate Director Investor Relations
QIAGEN GmbH | QIAGEN-Str. 1 | 40724 Hilden | Germany
Phone +49-2103-29-11457 | Fax +49-2103-29-21457